⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415811 | 0.84 | — | — | |
| SCHEMBL3411831 | 0.84 | NPC1 (0.37) | — | |
| SCHEMBL598956 | 0.79 | KDM4E (0.31) | — | |
| SCHEMBL2986949 | 0.77 | — | — | |
| SCHEMBL2479941 | 0.76 | — | — | |
| SCHEMBL2466724 | 0.76 | PPARD (0.35) | — | |
| SCHEMBL2415833 | 0.72 | — | — | |
| SCHEMBL17670672 | 0.72 | L3MBTL1 (0.33) | — | |
| SCHEMBL598958 | 0.71 | HTR2A (0.32) | — | |
| SCHEMBL4823005 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344125-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| US-20050164235-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue; drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs for hepatitis virus | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |